TY - JOUR
T1 - Profile of daprodustat in the treatment of renal anemia due to chronic kidney disease
AU - Ishii, Taisuke
AU - Tanaka, Tetsuhiro
AU - Nangaku, Masaomi
N1 - Funding Information:
M.N. has received research grant from JT , and Kyowa Kirin Co. Ltd., and personal fees from GlaxoSmithKline, Astellas, Mitsubishi T anabe Pharma Corporation, Bayer Y akuhin Ltd., T orii Pharmaceutical Co. Ltd, and AstraZeneca, outside the submitted work. T .T . has received research grant from JT and Bayer . T .I. declared no conflicts of interest. The authors report no other conflicts of interest in this work.
Publisher Copyright:
© 2021 Ishii et al.
PY - 2021
Y1 - 2021
N2 - Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to the stabilization of intracellular hypoxiainducible factor (HIF) 1α and HIF2α by PHD inhibition. Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysisand non-hemodialysis-dependent CKD patients. In addition, some international Phase 3 studies are underway to confirm these effects and reveal the safety profile. This article summarizes the development process and results of each clinical trial.
AB - Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to the stabilization of intracellular hypoxiainducible factor (HIF) 1α and HIF2α by PHD inhibition. Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysisand non-hemodialysis-dependent CKD patients. In addition, some international Phase 3 studies are underway to confirm these effects and reveal the safety profile. This article summarizes the development process and results of each clinical trial.
KW - Erythropoietin
KW - Hypoxia-inducible factor
KW - Iron
KW - Prolyl hydroxylase domain
UR - http://www.scopus.com/inward/record.url?scp=85101767843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101767843&partnerID=8YFLogxK
U2 - 10.2147/TCRM.S293879
DO - 10.2147/TCRM.S293879
M3 - Review article
AN - SCOPUS:85101767843
SN - 1176-6336
VL - 17
SP - 155
EP - 163
JO - Therapeutics and Clinical Risk Management
JF - Therapeutics and Clinical Risk Management
ER -